Scalable microfluidics that can address the challenge of delivery of large transgenes to therapeutic cells
To accelerate the manufacturing innovation, the goal of this project is to validate a cell engineering technology that uses a microfluidic transfection for delivery of therapeutic transgenes to four cell types of importance to the pharma industry.
Categories
Cell and Gene therapies
Equipment and Supplies
Project status
100% Completed
Industry Need
Cost of manufacturing genetically engineered cells for therapies is significant, with high process complexity, and variable cell product quality.
Solution
Validate a cell engineering technology that uses microfluidic transfection for delivery of therapeutic transgenes.
Outputs/Deliverables
Developed consumable transfection chip for T cells and iPSCs that was delivered to partners
Demonstrated first mechanoporation transfection of iPSCs with large CRISPR-correction plasmids
Demonstrated high efficiency T cell knockout editing using mechanoporation
Demonstrated clinical scale processing (>1B cells) of T cells
Additional Project Information (Members Only)
Login to the NIIMBL member portal to access more, including: